• 1
    European Center for Disease Prevention and Control. Enhanced monitoring of vaccine safety for 2009 pandemic vaccines. 27-2-2013.
  • 2
    Pandemrix: EPAR – Product Information. European Medicines Agency, 143. 27-2-2012.
  • 3
    Focetria: EPAR – Product Information. European Medicines Agency, 141. 14-6-2012.
  • 4
    Celvapan: EPAR – Product Information. 25-10-2012.
  • 5
    Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012; 7: e33536.
  • 6
    Persson I, Feltelius N. Registry study confirms increased risk of narcolepsy after vaccination with Pandemrix in children and adolescents and shows an increased risk in young adults. Lakemedelsverket Medical Products Agency. 26-3-0013. 17-6-2013.
  • 7
    Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 2013; 80: 131521.
  • 8
    Han F, Lin L, Warby SC, Faraco J et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011; 70: 4107. doi: 10.1002/ana.22587.
  • 9
    Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, Feltelius N. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population and register based cohort study with over two years of follow-up. J Intern Med 2013; doi: 10.1111/joim.12150
  • 10
    Lin L, Faraco J, Li R, Kadotani H et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 36576.
  • 11
    Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355: 3940.
  • 12
    Partinen M, Saarenpää-Heikkilä O, Ilveskoski I et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 2012; 7: e33723. doi: 10.1371/journal.pone.0033723. Epub 2012 Mar 28.
  • 13
    Hallmayer J, Faraco J, Lin L et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009; 41: 70811. doi: 10.1038/ng.372. Epub 2009 May 3. Erratum in: Nat Genet. 2009 Jul;41(7):859.
  • 14
    Steinman L. Autoimmune disease. Sci Am 1993; 269: 10614.
  • 15
    Morel S, Didierlaurent A, Bourguignon P et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29: 246173.
  • 16
    Khurana S, Verma N, Yewdell JW et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011; 3: 85ra48.
  • 17
    Carlson BC, Jansson AM, Larsson A, Bucht A, Lorentzen JC. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol 2000; 156: 205765.
  • 18
    Dunn SE, Youssef S, Golstein M et al. Isoprenoids Determine Th1/Th2 Fate in Pathogenic T Cells Providing A Mechanism for Modulation of Autoimmunity by Atorvastatin. J Exp Med 2006; 203: 40112.
  • 19
    Lang HL, Jacobsen H, Ikemizu S et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3: 9403.
  • 20
    Kaushansky N, Altmann DM, Ascough S, David CS, Lassmann H, Ben-Nun A. HLA-DQB1*0602 determines disease susceptibility in a new “humanized” multiple sclerosis model in HLA-DR15 (DRB1*1501;DQB1*0602) transgenic mice. J Immunol 2009; 183: 353141. doi: 10.4049/jimmunol.0900784. Epub 2009 Jul 31.
  • 21
    Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L. Osteopontin induced relapse and progression of autoimmune brain disease via enhanced survival of activated T cells. Nat Immunol 2007; 8: 7786.